

Special Issue

Vaccination Against Viral Hepatitis for Prevention and Treatment

Message from the Guest Editors

The World Health Organisation estimated that Hepatitis B and C viruses caused over a million deaths in 2022 with 304 million people chronically infected worldwide. There are >20 million hepatitis A and E virus infections each year, often resulting in debilitating symptoms and sometimes fulminant hepatitis. Vaccines play a central role in controlling viral hepatitis and reaching the WHO 2030 target to reduce new hepatitis infections by 90% from 2015 levels. This Special Issue aims to bring together original research articles and reviews on viral hepatitis and recent exciting advances:

- Strategies to increase coverage of existing viral hepatitis vaccines;
- Research into new prophylactic and therapeutic viral hepatitis vaccines, formulations, and delivery mechanisms;
- Ways to enhance the immunogenicity or safety of viral hepatitis vaccines;
- Immune responses to viral hepatitis vaccines;
- Epidemiological impact studies of viral hepatitis vaccines.

Guest Editors

Dr. Antony Black

School of Life Sciences, University of Westminster, London, UK

Dr. Monique Andersson

Department of Infection, University of Oxford, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

Deadline for manuscript submissions

31 August 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/226606

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers
Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).